Company: MIRA
Filing Date: 2025-06-17
Form Type: PREM14A
Source: 0001641172-25-015340
Chunk: 81

Company: MIRA PHARMACEUTICALS, INC.
Filing Date: 2025-06-17
Form: PREM14A
Chunk 81
---
 death and exposure to secondhand smoke are estimated at over $185 billion annually. Current medications, such as Varenicline and Bupropion, have serious side effects that may cause discontinuation. Varenicline side effects include suicidal ideation, nausea, sleep disturbance, unusual or strange dreams, constipation, gas, and vomiting. Bupropion is not suitable for patients with seizure disorders or a predisposition to seizures. Side effects include dry mouth, insomnia, and changes in mood or behavior (per the British Medical Journal).

Source: www.cdc.gov

Weight Loss Market Overview

As of March 26, 2025, current market estimates for weight loss drugs vary depending on the forecast period and source, but they reflect significant growth driven by surging demand and expanding applications. Based on available data, Bloomberg Intelligence estimates global weight loss drug sales at approximately $24.6 billion for 2025, reflecting a sharp increase from $14.8 billion in 2024 and $6.3 billion in 2023. This aligns with the rapid uptake of GLP-1 agonists like Wegovy and Zepbound. IQVIA’s 2024 outlook projected global spending on obesity medications could reach $131 billion by 2028, implying an annualized growth rate of about 27% from the $24 billion recorded in 2023. This suggests a 2025 figure potentially exceeding $40 billion if shortages ease and manufacturing capacity increases, though supply constraints remain a limiting factor. Analysts from BMO Capital Markets and Reuters cite forecasts of $150 billion annually by the early 2030s (around 2033), up from earlier estimates of $100 billion, driven by increasing supply, new entrants, and broader insurance coverage. Morgan Stanley offers a more conservative estimate of $77 billion by 2030, while Morningstar and Pitchbook project a potential $200 billion market by 2031, factoring in 16 new drugs expected by 2029. The U.S. market alone hit $11.9 billion in 2023 according to Marketdata LLC, doubling from $5.1 billion in 2022, suggesting that 2024 and 2025 estimates could climb higher as shortages resolve (e.g., the FDA removed Tirzepatide from its shortage list in December 2024). Many of the large pharmaceutical companies have show significant revenue increases in their weight loss and diabetes prescription drug sales.

Revenue Accelerators for Weight Loss Market

| Drug – Revenue